{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:01:09Z","timestamp":1793318469639,"version":"4.5.0"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Carbapenem resistant klebsiella pneumoniae infection increased the mortality rate of liver transplant recipients. This study aims to provide more evidence for the clinical diagnosis and treatment of carbapenem resistant klebsiella pneumonia infection in liver transplant recipients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study included liver transplant recipients who developed CRKP infections during the perioperative period from January 2019 to December 2024 at Beijing You\u2019an Hospital. Statistical analysis was performed on their clinical and outcomes characteristics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among the 48 liver transplant recipients with CRKP infections, the 30 days mortality rate and the 90 days mortality rate after infection was 25%(12\/48) and 31.25%(15\/48). The mortality rates of patients with abdominal cavity infections were significantly higher than those of other patients (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&amp;lt;\u00a00.05). The mortality rate of patients with mechanical ventilation and with septic shock during infection was higher (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&amp;lt;\u00a00.05). Among the initial laboratory indicators after patient infection, there were significant differences in platelet (PLT), procalcitonin (PCT), total bilirubin (TBIL), creatinine (CR), and urea (UR) between the survival group and the death group (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&amp;lt;\u00a00.05). Intra\u2212abdominal infection (OR\u00a0=\u00a07.413, 95% CI: 1.218-45.136,\n                      <jats:italic>p<\/jats:italic>\n                      =\u00a00.030) and septic shock (OR\u00a0=\u00a025.015, 95% CI: 4.128-151.594,\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt;\u00a00.001) were both independent risk factors for 90\u2212days mortality. The drug sensitivity results of CRKP strains from liver transplant recipients showed that the three drugs with the lowest resistance rates were ceftazidime-avibactam, polymyxin, and tigecycline. Different drugs and drug combinations did not cause differences in the all-cause mortality rates of patients after infection (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&amp;gt;\u00a00.05). The risk of death in patients who received effective antibiotics within 48 hours was reduced by 54.3% (HR\u00a0=\u00a00.457, 95% CI: 0.163-1.285,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.135), but due to the limited sample size, this result did not reach statistical significance.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Clinicians should remain vigilant for abdominal infections, promptly control the infection source, and recognize early signs of septic shock to initiate timely treatment\u2014key measures to reduce mortality for liver transplant recipients with CRKP infection. Additionally, effective antibiotic therapy within 48 hours after sampling may confer a survival benefit.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcimb.2026.1864183","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T04:30:29Z","timestamp":1784781029000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical characteristics and outcomes of liver transplant recipients with carbapenem resistant klebsiella pneumonia infection"],"prefix":"10.3389","volume":"16","author":[{"given":"Yan","family":"Dang","sequence":"first","affiliation":[{"name":"Department of Clinical Laboratory Center, Beijing Youan Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory Center, Beijing Youan Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gengxia","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Liver Transplantation Center, Beijing Youan Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory Center, Beijing Youan Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiurong","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory Center, Beijing Youan Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangfang","family":"Dai","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory Center, Beijing Youan Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhua","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory Center, Beijing Youan Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinli","family":"Lou","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory Center, Beijing Youan Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"107-13","DOI":"10.1006\/jsre.2000.6061","article-title":"Bilirubin impairs bactericidal activity of neutrophils through an antioxidant mechanism in vitro","volume":"96","author":"Arai","year":"2001","journal-title":"J. Surg. Res."},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2022.106554","article-title":"A retrospective observational cohort study of the clinical epidemiology of bloodstream infections due to carbapenem-resistant Klebsiella pneumoniae in an OXA-48 endemic setting","volume":"59","author":"Aslan","year":"2022","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B3","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s15010-024-02182-4","article-title":"The role of gut barrier dysfunction in postoperative complications in liver transplantation: pathophysiological and therapeutic considerations","volume":"52","author":"Assimakopoulos","year":"2024","journal-title":"Infection"},{"key":"B4","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1186\/s12879-016-1876-5","article-title":"Carbapenem-resistant klebsiella pneumoniae influences the outcome of early infections in liver transplant recipients","volume":"16","author":"Barchiesi","year":"2016","journal-title":"BMC Infect. Dis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1080\/23744235.2017.1354259","article-title":"Clinical outcomes associated with carbapenem resistant klebsiella pneumoniae (CRKP) in abdominal solid organ transplant (SOT) recipients","volume":"50","author":"Bias","year":"2018","journal-title":"Infect. Dis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.jgar.2025.01.009","article-title":"Clinical and molecular characteristics of KPC-producing Klebsiella pneumoniae bloodstream infections: Results of a multicentre study","volume":"41","author":"Brescini","year":"2025","journal-title":"J. Global Antimicrob. Resist."},{"key":"B7","doi-asserted-by":"publisher","first-page":"7191","DOI":"10.3748\/wjg.v26.i45.7191","article-title":"High mortality associated with gram-negative bacterial bloodstream infection in liver transplant recipients undergoing immunosuppression reduction","volume":"26","author":"Chen","year":"2020","journal-title":"World J. Gastroenterol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"5603","DOI":"10.2147\/IDR.S342163","article-title":"Ceftazidime-avibactam as salvage treatment for infections due to carbapenem-resistant Klebsiella pneumoniae in liver transplantation recipients","volume":"14","author":"Chen","year":"2021","journal-title":"Infection Drug Resistance"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1056\/NEJMra064928","article-title":"Infection in solid-organ transplant recipients","volume":"357","author":"Fishman","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1080\/17512433.2021.1901574","article-title":"Pharmacokinetic\/pharmacodynamic target attainment in critically ill renal patients on antimicrobial usage: focus on novel beta-lactams and beta lactams\/beta-lactamase inhibitors","volume":"14","author":"Gatti","year":"2021","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.ajic.2008.03.002","article-title":"CDC\/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute caresetting","volume":"36","author":"Horan","year":"2008","journal-title":"Am.J.Infect.Control."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2024.107152","article-title":"Efficacy of ceftazidime-avibactam in the treatment of carbapenem-resistant Klebsiella pneumoniae infections: focus on solid organ transplantation recipients","volume":"63","author":"Hu","year":"2024","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00213-21","article-title":"Overview of changes to the Clinical and Laboratory Standards Institute Performance Standards for Antimicrobial Susceptibility Testing, M100, 31st edition","volume":"59","author":"Humphries","year":"2021","journal-title":"J. Clin. Microbiol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"6211","DOI":"10.3748\/wjg.v20.i20.6211","article-title":"Bacterial infection after liver transplantation","volume":"20","author":"Kim","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v31.i8.98415","article-title":"Carbapenem-resistant Klebsiella pneumoniae infections after liver transplantation: Drug resistance, risk factors and impact on prognosis","volume":"31","author":"Liu","year":"2025","journal-title":"World J. Gastroenterol."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.00711-25","article-title":"Epidemiology, antimicrobial resistance, and risk factors of infection among liver transplant patients: a retrospective study 2010\u20132023","volume":"13","author":"Liu","year":"2025","journal-title":"Microbiol. Spectr."},{"key":"B17","doi-asserted-by":"publisher","first-page":"5011","DOI":"10.2147\/IDR.S376763","article-title":"Epidemiology, drug resistance, and risk factors for mortality among hematopoietic stem cell transplantation recipients with hospital-acquired Klebsiella pneumoniae infections: a single-center retrospective study from China","volume":"15","author":"Liu","year":"2022","journal-title":"Infection Drug Resistance"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e15285","article-title":"Epidemiology, drug resistance analysis and mortality risk factor prediction of gram-negative bacteria infections in patients with allogeneic hematopoietic stem cell transplantation","volume":"9","author":"Liu","year":"2023","journal-title":"Heliyon"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.976408","article-title":"Epidemic, risk factors of carbapenem-resistant Klebsiella pneumoniae infection and its effect on the early prognosis of liver transplantation","volume":"6","author":"Liu","year":"2022","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"612","DOI":"10.4254\/wjh.v16.i4.612","article-title":"Klebsiella pneumoniae infections after liver transplantation: drug resistance and distribution of pathogens, risk factors, and influence on outcomes","volume":"16","author":"Long","year":"2024","journal-title":"World J. Hepatol."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.04755-22","article-title":"Clinical outcomes and risk factors for death following carbapenem-resistant Klebsiella pneumoniae infection in solid organ transplant recipients","volume":"11","author":"Lu","year":"2023","journal-title":"Microbiol. Spectr."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1016\/j.transproceed.2024.10.016","article-title":"Thrombocytopenia predicts poor prognosis of liver transplantation","volume":"56","author":"Ma","year":"2024","journal-title":"Transplant. Proc."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics15151866","article-title":"Impact of perioperative antibiotic prophylaxis targeting multidrug-resistant gram-negative bacteria on postoperative infection rates in liver transplant recipients","volume":"15","author":"Massa","year":"2025","journal-title":"Diagnostics"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.ajt.2023.03.011","article-title":"Efficacy of ceftazidime-avibactam in solid organ transplant recipients with bloodstream infections caused by carbapenemase-producing Klebsiella pneumoniae","volume":"23","author":"P\u00e9rez-Nadales","year":"2023","journal-title":"Am. J. Transplant."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000023169","article-title":"High prevalence of multidrug-resistant gram-negative bacterial infection following pediatric liver transplantation","volume":"99","author":"Phichaphop","year":"2020","journal-title":"Med. (Baltim)."},{"key":"B26","doi-asserted-by":"publisher","first-page":"83","DOI":"10.4254\/wjh.v3.i4.83","article-title":"Infections in liver transplant recipients","volume":"3","author":"Romero","year":"2011","journal-title":"World J. Hepatol."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.71364","article-title":"Pre-transplant serum procalcitonin as a predictor of early post-transplant sepsis and mortality after living donor liver transplantation: a prospective observational study","volume":"16","author":"Satija","year":"2024","journal-title":"Cureus"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2021.791574","article-title":"Molecular surveillance of carbapenem-resistant gramnegative bacteria in liver transplant candidates","volume":"12","author":"Schultze","year":"2021","journal-title":"Front. Microbiol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1007\/s11596-021-2397-z","article-title":"Treatment of donor-derived carbapenem-resistant Klebsiella pneumoniae infection after renal transplantation with tigecycline and extended-infusion meropenem","volume":"41","author":"Wang","year":"2021","journal-title":"Curr. Med. Sci."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1007\/s40121-022-00649-1","article-title":"Drug resistance and risk factors for acquisition of gram-negative bacteria and carbapenem-resistant organisms among liver transplant recipients","volume":"11","author":"Wu","year":"2022","journal-title":"Infect. Dis. Ther."},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2024.1404404","article-title":"Clinical outcomes and risk factors for mortality in recipients with carbapenem-resistant gram-negative bacilli infections after kidney transplantation treated with ceftazidime-avibactam: a retrospective study","volume":"14","author":"Zhang","year":"2024","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"5165","DOI":"10.2147\/IDR.S343505","article-title":"Efficacy of ceftazidime-avibactam in the treatment of carbapenem-resistant Klebsiella pneumoniae infection after kidney transplantation","volume":"14","author":"Zhang","year":"2021","journal-title":"Infection Drug Resistance"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1007\/s40121-022-00682-0","article-title":"Ceftazidime\/avibactam-based versus polymyxin B-based therapeutic regimens for the treatment of carbapenem-resistant Klebsiella pneumoniae infection in critically ill patients: a retrospective cohort study","volume":"11","author":"Zheng","year":"2022","journal-title":"Infect. Dis. Ther."},{"key":"B34","doi-asserted-by":"publisher","first-page":"6471","DOI":"10.2147\/IDR.S381265","article-title":"Effect of carbapenem-resistant Klebsiella pneumoniae infection on the clinical outcomes of kidney transplant recipients","volume":"15","author":"Zheng","year":"2022","journal-title":"Infection Drug Resistance"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.micinf.2025.105563","article-title":"Microbiology and predictors of mortality in haematological Malignancy patients with gram-negative bacterial bloodstream infections","volume":"27","author":"Zheng","year":"2025","journal-title":"Microbes Infection"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1007\/s40121-021-00479-7","article-title":"Ceftazidime-avibactam in combination with in vitro non-susceptible antimicrobials versus ceftazidime-avibactam in monotherapy in critically ill patients with carbapenem-resistant Klebsiella pneumoniae infection: a retrospective cohort study","volume":"10","author":"Zheng","year":"2021","journal-title":"Infect. Dis. Ther."},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1777244","article-title":"The species, distribution, resistance of donor-derived pathogens and their impact on solid organ transplant recipients","author":"Zhou","year":"2026","journal-title":"Front. Immunol"}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2026.1864183\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T04:30:36Z","timestamp":1784781036000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2026.1864183\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":37,"alternative-id":["10.3389\/fcimb.2026.1864183"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2026.1864183","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,23]]},"article-number":"1864183"}}